Earnings summaries and quarterly performance for Imunon.
Executive leadership at Imunon.
Stacy Lindborg
Detailed
Chief Executive Officer and President
CEO
DG
David Gaiero
Detailed
Chief Financial Officer
DF
Douglas Faller
Detailed
Chief Medical Officer
KA
Khursheed Anwer
Detailed
Executive Vice President and Chief Scientific Officer
MT
Michael Tardugno
Detailed
Executive Chairman
SE
Susan Eylward
Detailed
General Counsel and Corporate Secretary
Board of directors at Imunon.
Research analysts who have asked questions during Imunon earnings calls.
DB
David Bautz
Zacks Small Cap Research
4 questions for IMNN
Also covers: ARMP, AURX, BCLI +1 more
James Molloy
Alliance Global Partners
4 questions for IMNN
Also covers: ABEO, ACXP, AIM +11 more
BK
Brian Kemp Dolliver
Brookline Capital Markets, LLC
2 questions for IMNN
Also covers: , BIOX, DARE +6 more
Emily Bodnar
H.C. Wainwright & Co.
2 questions for IMNN
Also covers: AGEN, AGIO, ATOS +6 more
Kemp Dolliver
Brookline Capital Markets
1 question for IMNN
Also covers: BIOX, EYEN, ICCM +4 more
Laura Suriel
Alliance Global Partners
1 question for IMNN
Also covers: BCDA, GOVX, INMB
Will Hidell
Brookline Capital Markets
1 question for IMNN
Also covers: DARE, LSTA, OTLK
Recent press releases and 8-K filings for IMNN.
Imunon Announces Pricing of $7.0 Million Registered Direct Offering
IMNN
New Projects/Investments
- IMUNON, Inc. announced a registered direct offering on December 30, 2025, priced at-the-market under NASDAQ rules.
- The offering includes 1,939,114 shares of common stock (or pre-funded warrants) and warrants to purchase up to 1,939,114 shares of common stock, with a combined purchase price of $3.61 per share (or pre-funded warrant) and warrant.
- The company anticipates receiving gross proceeds of approximately $7.0 million from the offering, which is expected to close around December 31, 2025.
- IMUNON plans to use the proceeds for general corporate purposes, including research and development activities, capital expenditures, and working capital.
Dec 31, 2025, 1:00 PM
Imunon Reports Q3 2025 Financial Results and OVATION 3 Trial Progress
IMNN
Earnings
Guidance Update
Delisting/Listing Issues
- Imunon reported cash and cash equivalents of $5.3 million as of September 30, 2025, with a projected operating runway into mid-Q1 2026. The company raised $4.5 million during Q3 2025 through warrant exercises and ATM usage.
- For Q3 2025, the net loss was $3.4 million, or $1.16 per share, compared to $4.8 million, or $3.76 per share, in Q3 2024. Operating expenses for the nine months ended September 30, 2025, were 31% lower than the prior year, including a 44% decrease in R&D expenses.
- Enrollment for the OVATION 3 pivotal phase III trial for advanced ovarian cancer is surging ahead of plan. Imunon also achieved NASDAQ compliance, with the matter formally closed on September 3, 2025.
Nov 13, 2025, 4:00 PM
Imunon, Inc. Reports Q3 2025 Financial Results and Provides Business Update
IMNN
Earnings
New Projects/Investments
Guidance Update
- Imunon, Inc. reported a net loss of $3.4 million, or $1.16 per share, for the third quarter of 2025, and a net loss of $10.3 million, or $5.53 per share, for the nine months ended September 30, 2025.
- Operating expenses decreased by 30% to $3.5 million for Q3 2025 and by 31% to $10.4 million for the nine months ended September 30, 2025, compared to the respective prior year periods.
- As of September 30, 2025, cash and cash equivalents totaled $5.3 million, which the company believes is sufficient to fund planned operations into the first quarter of 2026.
- The company is advancing its Phase 3 OVATION 3 Study for IMNN-001 in advanced ovarian cancer, with the first patient dosed in Q3 2025, and recent presentations highlighted a median 13-month overall survival benefit from the Phase 2 OVATION 2 trial.
- IMUNON also presented proof-of-concept clinical trial results for its PlaCCine® DNA vaccine technology (IMNN-101) at vaccine conferences in October and November 2025, demonstrating safety, immunogenicity, and differentiating features.
Nov 13, 2025, 12:48 PM
IMUNON Regains Nasdaq Compliance
IMNN
Delisting/Listing Issues
Dividends
New Projects/Investments
- IMUNON, Inc. (Nasdaq: IMNN) has regained compliance with the Nasdaq minimum bid price requirement for continued listing on The Nasdaq Capital Market.
- The company received written notification from the Nasdaq Hearings Panel on August 27, 2025, confirming compliance with the $1.00 minimum closing bid price requirement.
- As a result, IMUNON common stock will continue uninterrupted trading on The Nasdaq Capital Market.
- This compliance follows a recent 15% stock dividend to shareholders of record as of August 7, 2025.
- The company also noted the successful initiation of its Phase 3 OVATION 3 trial in North America for its lead clinical program, IMNN-001.
Aug 28, 2025, 12:08 PM
Imunon Reports Positive Phase 2 IMNN-001 Data and Plans Phase 3 Initiation
IMNN
New Projects/Investments
Guidance Update
Management Change
- Imunon reported positive results from its Phase 2 OVATION 2 study for IMNN-001 in advanced ovarian cancer, demonstrating an improvement in median overall survival of 13 months over standard of care in the intent-to-treat population.
- The company plans to initiate its pivotal Phase 3 OVATION 3 study for IMNN-001 in March 2025, with a 500-patient study targeting newly diagnosed advanced ovarian cancer and two interim analyses planned.
- Dr. Douglas Faller joined Imunon as Chief Medical Officer in February 2025, bringing over 30 years of experience in oncology and drug development.
- Imunon is actively seeking to raise capital for the Phase 3 trial, with ongoing discussions with viable investors, and noted the potential for accelerated approval for IMNN-001 given the strengthening data and the upcoming Phase 3 study.
Feb 27, 2025, 4:00 PM
Fintool News
In-depth analysis and coverage of Imunon.
Quarterly earnings call transcripts for Imunon.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more